X4 Pharmaceuticals

X4 Pharmaceuticals

Edit info

  • Founded: 2012
  • Location: Boston, MA
  • Employee range: 50 - 200
  • Clinical stage: NDA
  • Therapy area: WHIM syndrome
  • Drug types: GEN, IMM, RAR, INF, DRM, PED, HEM, ONC
  • Lead product: Mavorixafor
  • Funding: $65M stock May 2023; $65M stock Dec 2022; $55M stock Jun 2022; $55M stock Mar 2021; $27M Nov 2017


x4pharma.com

linkedin.com

job board


Business:

Oral small molecules

Drug notes:

Also Clin2 multiple neutropenias, Clin1b Waldenstrom's macroglobulinemia; X4P-002 Clin0 oncology; X4P-003 Clin0 neutropenic disorder

About:

X4 Pharmaceuticals is developing novel small molecule therapies that target the X4 receptor. The X4 receptor is a G protein-coupled receptor (GPCR) that plays a key role in the inflammatory response. When the X4 receptor is activated, it signals for the recruitment of leukocytes, which are white blood cells that help to fight infection and repair damaged tissue. However, overactivation of the X4 receptor can lead to chronic inflammation, which is associated with a variety of diseases, including fibrosis. X4 Pharmaceuticals' X4 receptor modulators are designed to selectively modulate the X4 receptor to reduce inflammation and fibrosis without causing unwanted side effects.

X4 Pharmaceuticals
Senior Medical Director, Clinical Development
Boston, MA|18 days ago
Apply
X4 Pharmaceuticals
Senior Manager, Infrastructure Operations & Securi...
Boston, MA|99 days ago
X4 Pharmaceuticals
Vice President, Information Technology
Boston, MA|Not provided


© 2025 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com